OBJECTIVE: Transplant @entity4288 is the major determinant for long-term survival of cardiac transplants. @entity53 treatment inhibits @entity8 . The objective of this study is to determine, in the absence of immunosuppression, the temporal effect of @entity53 treatment on the expression of insulin-like growth factor, platelet-derived growth factor, basic fibroblast growth factor, and major histocompatibility complex class II antigen in @entity35 aortic allografts. METHODS: Orthotopic abdominal aortic allograft transplantation was performed in male @entity35 with Brown- @entity35 used as donors and Lewis @entity35 as recipients. The recipients (n = 50) were treated with @entity53 20 micrograms/kg per day or placebo by osmotic minipump for 2 days before the operation and until they were put to death on postoperative days 1, 3, 7, 14, or 21. The allografts were harvested and insulin-like growth factor, platelet-derived growth factor, basic fibroblast growth factor, and major histocompatibility complex class II antigen expression were determined by immunohistochemical staining. Myointimal thickening was measured by morphometric analysis. RESULTS: In the placebo-treated group, insulin-like growth factor protein progressively increased in all three layers of the allograft, whereas platelet-derived growth factor protein peaked at day 3 and basic fibroblast growth factor protein increased only moderately. @entity53 treatment inhibited the continuous increase in insulin-like growth factor expression, the peak in platelet-derived growth factor expression at day 3, the moderate-basic fibroblast growth factor increase at day 21, and major histocompatibility complex class II antigen expression in all three layers of the allograft at day 21. Intimal thickening of allografts from @entity53 -treated recipients was twofold to threefold less than that of the placebo-treated recipients at day 21. CONCLUSION: The development of @entity8 is associated with an early alloimmune response involving sustained increase in insulin-like growth factor expression. @entity53 treatment of the @entity8 and @entity851 factor and major histocompatibility complex class II antigen expression but not platelet-derived growth factor or basic fibroblast growth factor in all three layers of the allograft during the early posttransplantation alloimmune rejection phase.

Specific effects of estrogen on growth factor and major histocompatibility complex class II antigen expression in XXXX aortic allograft.

@entity8 :: ('MESH:D007674', 'Disease') :: ['recipient inhibits transplant arteriosclerosis', 'transplant arteriosclerosis'] @entity851 :: ('MESH:D006130', 'Disease') :: ['suppresses insulin-like growth'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['Estradiol', 'estradiol'] @entity35 :: ('10116', 'Species') :: ['rat', 'Norway rats', 'rats'] @entity4288 :: ('MESH:D001161', 'Disease') :: ['arteriosclerosis']
@entity35 :: (10116,Species) :: ['rat']
